Buy CYTX Before the Street Notices

This is clearly an exciting time for Cytori Therapeutics (CYTX), as the company has begun to record product sales revenues from early-adopter Celution System placements in Europe and Asia.

Additionally, sales of StemSource cell banking are also now beginning to ramp. Ultimately, the clinical data will determine the pace at which the ramp continues in the next several years.

We have been encouraged by the small clinical data seen so far using Cytori's technology. We think the company is in store to report a solid 4th quarter, and the Street has yet to take notice of the upside that exists over the next few years.

Today's price represents a very attractive entry point, in our view. We are maintaining our Buy rating.

Read the full analyst report on CYTX